The goal of this clinical research study is to find the highest safe dose of olaparib that can be combined with chemotherapy drugs and stem cell transplantation to treat patients with relapsed and refractory germ cell cancer. The safety and effectiveness of this treatment combination therapies will also be studied.

Start Date01 Mar 2027

Sponsor / Collaborator-

NCT05403723

/ SuspendedPhase 1IIT

A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination With Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer

This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).

Start Date30 Jan 2027

Sponsor / Collaborator

University of Maryland Baltimore

[+1]

NCT07258147

/ Not yet recruitingPhase 2IIT

Clinical Study on the Efficacy and Safety of Radiotherapy Combined With Immunotherapy and Chemotherapy for Pre-treated Patients With Small Cell Lung Cancer and Liver Metastases

This is clinical trial evaluating the safety and efficacy of radiotherapy combined with immunotherapy and chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) and liver metastases.

Start Date31 Oct 2026

Sponsor / Collaborator

Sichuan University

100 Clinical Results associated with Etoposide

100 Translational Medicine associated with Etoposide

100 Patents (Medical) associated with Etoposide

26,290

Literatures (Medical) associated with Etoposide

31 Dec 2026·Gut Microbes

Gut bacterial O -demethylation modulates systemic exposure to oral etoposide

Article

Author: Lee, Seongsoo ; Lee, Hyunwoo ; Sullivan, Peter ; Ilktach, Giokdjen ; Cooper, Bruce R. ; Shin, Jongoh ; Jeong, Hyunyoung ; Cho, Byung-Kwan ; Lee, Wooin ; Kyawt, Toe Ein ; Orjala, Jimmy ; Tripathi, Ashutosh ; Weilbaker, Holly A. ; Won, Kyoung-jae ; Armstrong, Abigail T. ; Ko, Yeonju

Gut microbial O-demethylation has been reported for plant-derived dietary compounds containing O-methylated aromatic(s). However, the significance of gut microbial O-demethylation in drug metabolism and disposition remains unexplored. This study examined 64 clinically used oral drugs containing one or more methoxylated aromatics for gut microbial O-demethylation using high-resolution mass spectrometry (HRMS). For 35 of the tested drugs, including the anticancer agent etoposide, we detected metabolites corresponding to O-demethylation (i.e., a mass difference of -14 and its multiples) when individual drugs were incubated with mouse cecal contents. We confirmed that the O-demethylated metabolite (M1) of the model drug etoposide is etoposide catechol using HRMS and proton nuclear magnetic resonance spectroscopy. By testing an in-house collection of 56 gut bacteria individually, we identified seven previously unknown gut bacterial species that exhibit etoposide O-demethylating activity. Etoposide anticancer therapy has been associated with an increased risk of acute myeloid leukemia. We demonstrated that M1 is more genotoxic to myeloid cells when it is orally administered to mice, whereas M1 is less cytotoxic against MCF-7 and HeLa cancer cells than the parent etoposide, suggesting that the gut microbiota may contribute to the secondary genotoxicity of etoposide via O-demethylation. Comparative pharmacokinetic analysis of orally administered etoposide in control and antibiotic-treated mice showed that systemic exposure to etoposide increased 1.9-fold, while M1 exposure decreased 3.7-fold in antibiotic-treated mice, suggesting that gut microbial O-demethylation is a significant determinant of etoposide metabolism and disposition. Collectively, our study reveals the prevalence of gut bacteria with O-demethylation activity, illustrates the contribution of gut microbial O-demethylation to altering drug efficacy and toxicity with the model drug etoposide, and provides a knowledge basis for in-depth characterization of other drugs identified as being susceptible to gut microbial O-demethylation.

31 Dec 2026·Future Science OA

Drug-Induced liver injury with adebrelimab: how to assess causality using the updated RUCAM?

Article

Author: Wu, Li-Peng ; Liu, Li ; Liu, Tao ; Min, Jie ; Sun, Si-Qin ; Xi, Heng

AIM:

To report a case of Adebrelimab-related liver injury and emphasize the role of the updated RUCAM in causality assessment for suspected immune checkpoint inhibitor-induced hepatotoxicity.

OBSERVATION:

A 51-year-old male with small-cell lung cancer developed severe jaundice four days after his last dose of etoposide/carboplatin combined with adebrelimab, occurring after nine cycles of therapy (at 5 months) and later than the onset time described in the drug label. Baseline liver function was normal, and there was no history of hepatobiliary disease. Physical examination revealed jaundice and scleral icterus. The updated RUCAM score was 8, indicating a highly probable relationship between the regimen and liver injury, while the simplified AIH score (<6) ruled out autoimmune hepatitis. The patient's liver enzymes and bilirubin normalized, and clinical symptoms improved following treatment with low-dose methylprednisolone (1 mg/kg/d) and other supportive measures.

CONCLUSION:

This case highlights the value of applying the updated RUCAM to reliably distinguish drug-induced liver injury from other etiologies in immune checkpoint inhibitor recipients, thereby guiding appropriate clinical management.

01 Dec 2026·JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Computational study on QSAR modeling, molecular docking, and ADMET profiling of pyrazole-modified catalpol derivatives as prospective dual inhibitors of VEGFR-2/BRAF V600E

Article

Author: Mandal, Manab ; Pal, Sumanta ; Ghosh, Narendra Nath ; Singh, Vivek Dutta ; Pati, Soumen Kumar

Pancreatic and Esophageal cancers are highly aggressive with high mortality and limited treatment, causing over 466,000 and 544,100 deaths worldwide in 2020 respectively. This highlights the urgent need for safer,and effective anticancer agents. Catalpol, a natural iridoid glycoside, shows anticancer potential, but due to its poor drug-like properties it requires structural modification. This study investigates pyrazole-modified catalpol derivatives as dual inhibitors for these cancers using Quantitative Structure Activity Relationship (QSAR) modelling, molecular docking, and pharmacokinetic studies. We analyzed fourteen pyrazole-modified catalpol derivatives with reported IC50values against four cancer cell lines(BxPC-3, PANC-1, Eca109, and EC9706). The molecules were optimized using DensityFunctional Theory (DFT), and 2D molecular descriptors were calculated using PaDEL. QSAR models were developed by utilizing a Genetic Function Algorithm (GFA) and Multiple Linear Regression (MLR) and validated using statistical metrics such as R², Q², R²adj, and R²pred. Docking studies targeted VEGFR-2 and BRAF V600E kinases using AutoDockVina, while ADMET and drug-likeness properties were predicted using SwissADME and pkCSM tools. The external validation R²pred values for BxPC-3, PANC-1, Eca109, and EC9706 cell lines were 0.9412, 0.9535, 0.9981, and 0.9935, respectively. Among the derivatives, compound 3k showed the highest binding affinity for VEGFR-2 (- 8.18 kcal/mol) and BRAF (- 8.64 kcal/mol), surpassing the control drugs etoposide (- 8.00 kcal/mol) and dabrafenib (- 8.15 kcal/mol) respectively. ADMET analysis confirmed good intestinal absorption, limited blood-brain barrier penetration, non-toxicity, acceptable total clearance, and compliance with Lipinski's rule. Overall, the study suggests that pyrazole-modified catalpol derivatives, especially compound 3k, are promising multi-target inhibitors for pancreatic and esophageal cancers, justify further in-vitro and in-vivo studies.

367

News (Medical) associated with Etoposide

25 Sep 2026

·pmlive.com

MHRA approves Pharma Mar’s lurbinectedin for extensive-stage small cell lung cancer

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pharma Mar’s lurbinectedin (Zepzelca) to treat adults with extensive-stage small cell lung cancer (SCLC). The treatment is in combination with atezolizumab as maintenance treatment in adults whose cancer has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide. Lurbinectedin works by attaching to DNA inside cancer cells. This damages the DNA and interferes with the growth and multiplication of cancer cells, leading to cancer cell death. It also reduces the activity of certain immune cells that help tumours grow. The treatment is given as an intravenous infusion over one hour. The recommended dose is administered once every 21 days. This approval was based on a main study involving 483 adults with extensive-stage SCLC. Patients receiving lurbinectedin in combination with atezolizumab as maintenance treatment lived for an average of 13.2 months, compared with 10.6 months for those receiving atezolizumab alone. Patients receiving lurbinectedin plus atezolizumab also lived for an average of 5.4 months without their disease getting worse, compared with 2.1 months for those receiving atezolizumab alone. Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, said: “The approval of lurbinectedin provides a new treatment option for adults with extensive-stage small cell lung cancer whose disease has not progressed following initial treatment with atezolizumab, carboplatin and etoposide.

Clinical ResultDrug Approval

23 Sep 2026

·www.biospace.com

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place on October 23-27, 2026, in Madrid, Spain. Notably, results from two positive Phase III studies evaluating the savolitinib and osimertinib combination have been selected for oral presentations. Results from the global SAFFRON study will be featured in the Presidential Symposium session, while results from the SANOVO study in China will be presented in a Proffered Paper session, both highlighting important new clinical data. Having two Phase III studies featured as late-breaking abstracts underscores the potential of this all-oral, chemo-free combination to deliver meaningful advancements for patients with non-small cell lung cancer (“NSCLC”). The SAFFRON Global Phase III Study has been selected for a Presidential Symposium oral presentation. The study evaluated the combination in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC with MET overexpression or amplification following disease progression on osimertinib. The trial reported positive high-level results on August 17, 2026, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (“PFS”) and overall survival (“OS”) compared to doublet platinum-based chemotherapy. The SANOVO China Phase III Study has been selected for a Proffered Paper oral presentation. The study evaluated the combination in previously untreated patients with locally advanced or metastatic NSCLC harboring activating EGFR mutations and MET overexpression. The trial reported positive high-level results on August 31, 2026, demonstrating a statistically significant and clinically meaningful improvement in PFS and a clinically meaningful benefit in OS versus osimertinib monotherapy. Details of the presentations are as follows: Abstract title Presenter / Lead author Presentation details SPONSORED STUDIES Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results Shun Lu (Shanghai, China) LBA6 Presidential Symposium II Alicante Auditorium - Hall 6 Sunday, October 25, 2026 16:30 - 18:15 CEST Savolitinib or Placebo Combined with Osimertinib in Treatment-Naïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results from the Phase 3 SANOVO Study Yi-Long Wu (Guangzhou, China) LBA69 Proffered paper 2: NSCLC, metastatic Alicante Auditorium - Hall 6 Monday, October 26, 2026 08:30 - 10:00 CEST Updated results from a fruquintinib Expanded Access Program for patients with previously treated metastatic colorectal cancer Stefan Kasper (Essen, Germany) 848P Poster Session: Colon cancer Association between dose adjustment and treatment outcomes in patients with advanced renal cell carcinoma receiving fruquintinib plus sintilimab: A post-hoc analysis of the FRUSICA-2 trial Yuanyuan Qu (Shanghai, China) 3655eP E-poster Session: Renal cancer Efficacy of fruquintinib plus sintilimab in special populations with advanced renal cell carcinoma: A subgroup analysis of FRUSICA-2 study Kaiwei Yang (Beijing, China) 3667eP E-poster Session: Renal cancer Final phase 2 analysis of surufatinib plus camrelizumab, nab-paclitaxel and gemcitabine in first-line metastatic pancreatic cancer Shukui Qin (Nanjing, China) 3156P Poster Session: Pancreatic cancer INVESTIGATOR-INITIATED STUDIES Fruquintinib plus capecitabine maintenance after first-line anti-EGFR antibody plus chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer: A phase Ib/II study Lin Yang/ Letian Zhang (Beijing, China) 877eP E-poster Session: Colon cancer Real-world effectiveness and safety of fruquintinib in patients with metastatic colorectal cancer in Spain: The FrESP study Ana Fernandez Montes (Ourense, Spain) 880eP E-poster Session: Colon cancer CONCEPT (COmbinatioN of CEtuximab Plus fruquintinib Treatment ± immunotherapy): A multicenter, randomized, open-label phase II trial in first-line pMMR RAS/BRAF wild-type unresectable metastatic colorectal cancer Kefeng Ding (Hangzhou, China) 890eP E-poster Session: Colon cancer A real-world study of low-dose fruquintinib combined with trifluridine/tipiracil hydrochloride (TAS-102) in the third-line and beyond treatment of metastatic colorectal cancer Yuehong Cui/ Li Liang (Shanghai, China) 903eP E-poster Session: Colon cancer Real-world outcomes with fruquintinib in heavily pretreated metastatic colorectal cancer: Impact of patient and disease characteristics Maria Maddalena Laterza (Pozzuoli, Italy) 964eP E-poster Session: Colon cancer A phase II, open-label, randomized study of doublet chemotherapy (FOLFOX or FOLFIRI) plus fruquintinib compared with doublet chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab in second line setting for a metastatic colorectal cancer: ULYSSE- FFCD2406 - PRODIGE115 (trials in progress) Jean Marc Phelip (Saint-Étienne, France) 991eTiP E-poster Session: Colon cancer Phase II study of fruquintinib plus utidelone in platinum-resistant recurrent ovarian cancer (FRUTD Trial) Zheng Feng (Shanghai, China) 1283P Poster Session: Gynaecological cancers Fruquintinib plus eribulin in patients with metastatic HR+, HER2 - breast cancer after progression on endocrine therapy plus CDK4/6 inhibitor: Updated results from a phase II study Yuan Yuan (Nanjing, China) 1896eP E-poster Session: HR+ breast cancer Fruquintinib plus sintilimab and XELOX as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, open-label, multicenter phase II study Hua Wang (Nanchang, China) 2980eP E-poster Session: Oesophagogastric cancer Fruquintinib plus cadonilimab and S-1 in previously treated unresectable locally advanced or metastatic esophageal squamous cell carcinoma: preliminary efficacy and safety results from a phase Ib/II study Huiyan Luo (Guangzhou, China) 2981eP E-poster Session: Oesophagogastric cancer Nanoliposomal irinotecan (nal-IRI) combined with fruquintinib as second-line treatment for advanced gastric cancer: A single-arm, open-label, dose-escalation and expansion phase I/II trial Jieer Ying/ Qi Xu (Hangzhou, China) 2986eP E-poster Session: Oesophagogastric cancer FRUQUITAS trial: ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma David Tougeron (Poitiers, France) 3079eTiP E-poster Session: Oesophagogastric cancer CHOICE III: short-course preoperative radiotherapy followed by fruquintinib plus anti–PD-1 antibody (serplulimab) for neoadjuvant treatment of pMMR/MSS mid-to-low locally advanced rectal cancer: A single-arm, single-center, prospective phase II study Wei Zhang (Shanghai, China) 3582eTiP E-poster Session: Rectal and anal cancer First-line fruquintinib plus serplulimab for metastatic non-clear cell renal cell carcinoma: Updated results from the phase II FRONTIER study Jiwei Huang (Shanghai, China) 3614P Poster Session: Renal cancer Latest efficacy and safety analysis of surufatinib combined with EP regimen and serplulimab as first-line treatment for extrapulmonary neuroendocrine carcinoma Tao Zhang/ Zhenyu Lin (Wuhan, China) 2394RO Rapid Oral Session: NETs and endocrine tumours Pamplona Auditorium - Hall 5 Friday, October 23, 2026 16:15 - 17:45 CEST Surufatinib combined with toripalimab and nab-paclitaxel/ gemcitabine chemotherapy as first-line treatment for advanced pancreatobiliary-type ampullary carcinoma: A prospective phase II Clinical Trial Juan Du (Nanjing, China) 507eP E-poster Session: Biliary tract cancer, incl. cholangiocarcinoma Efficacy and safety of surufatinib in combination with CAPTEM in advanced G2/G3 Neuroendocrine Tumors: Results from a single-arm, phase II Trial Wei Wang (Guangzhou, China) 2403P Poster Session: Neuroendocrine tumours Surufatinib plus S-1/temozolomide as first-line therapy in MGMT-low advanced pancreatic neuroendocrine tumours (SUSTEM-p): An open-label, single-centre phase Ib/II trial Yihebali Chi (Beijing, China) 2411P Poster Session: Neuroendocrine tumours Updated results of a prospective, open-label study of surufatinib plus CAPTEM as conversion therapy for unresectable pancreatic neuroendocrine tumors Ziyao Wang (Chengdu, China) 2412P Poster Session: Neuroendocrine tumours Matching-adjusted indirect comparison of surufatinib versus high-dose OCT-LAR in patients with advanced GEP-NETs who progressed on prior SSA Therapy Jianming Xu (Beijing, China) 2415P Poster Session: Neuroendocrine tumours Surufatinib combined with octreotide LAR for the treatment of G1/G2 GEP-NETs: A single-arm, prospective, open-label phase II study Xiaofeng Sun (Nanjing, China) 2439eP E-poster Session: Neuroendocrine tumours Six weeks of induction gemcitabine plus nab paclitaxel (AG) followed by sequential surufatinib plus AG or AG alone as first line therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC): A single center, two cohort, phase II study Jin Xu/ Jialin Li (Shanghai, China) 3168P Poster Session: Pancreatic cancer A phase Ib/II study of radiotherapy combined with surufatinib and sintilimab for localized high-risk limb and trunk soft tissue sarcomas: A prospective single-center trial Yan Wang (Shanghai, China) 3739P Poster Session: Sarcoma Surufatinib plus serplulimab, etoposide, and carboplatin as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC): Updated results from a single-arm, phase Ia/Ib trial Haipeng Xu/ Longfeng Zhang (Fuzhou, China) 3831P Poster Session: Small cell lung cancer About Fruquintinib Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE ® . Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA ® . About Savolitinib Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS ® . About Surufatinib Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA ® . HUTCHMED currently retains all rights to surufatinib worldwide. About HUTCHMED HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: or follow us on LinkedIn . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, surufatinib and savolitinib, the further clinical development for fruquintinib, surufatinib and savolitinib, its expectations as to whether any studies on fruquintinib, surufatinib and savolitinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, surufatinib and savolitinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, surufatinib and savolitinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as sintilimab and toripalimab as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. CONTACTS Investor Enquiries +852 2121 8200 / ir@hutch-med.com Media Enquiries FTI Consulting – +44 20 3727 1030 / HUTCHMED@fticonsulting.com Ben Atwell / Tim Stamper +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile) Brunswick – Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com Panmure Liberum Nominated Advisor and Joint Broker Atholl Tweedie / Emma Earl / Rupert Dearden +44 20 7886 2500 Cavendish Joint Broker Geoff Nash / Nigel Birks +44 20 7220 0500 Deutsche Numis Joint Broker Duncan Monteith / Ramin Naji +44 20 7545 8000

Clinical ResultPhase 2Phase 3ImmunotherapyLicense out/in

11 Sep 2026

·pmlive.com

AstraZeneca shares phase 3 results for Imfinzi plus Imdelltra in extensive-stage small cell lung cancer

AstraZeneca has shared phase 3 results for Imfinzi plus Imdelltra in extensive-stage small cell lung cancer (ES-SCLC). The DeLLphi-305 phase 3 trial showed Imfinzi (durvalumab) plus Amgen’s Imdelltra (tarlatamab) demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) versus Imfinzi alone as a 1st-line maintenance treatment. The trial included patients with ES-SCLC who had not progressed following standard induction treatment with Imfinzi in combination with platinum chemotherapy (either carboplatin or cisplatin) and etoposide. Imfinzi plus tarlatamab also demonstrated a statistically significant improvement in progression-free survival (PFS) and objective response rate. Jacob Sands, Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, said: “Given the aggressive nature of small cell lung cancer, many patients quickly relapse on current therapy and never reach second-line treatment. These patients do not have time to wait, making substantial progress in the first-line setting critically important. “[This trial] represents an unprecedented milestone and suggests we may be entering a new era where meaningfully longer survival is possible for more patients.” In 2026, an estimated 195,000 people globally will be treated for ES-SCLC, a highly aggressive, fast-growing form of lung cancer characterised by rapid tumour progression and metastatic spread to organs such as the brain and liver. Immune checkpoint inhibitors such as Imfinzi have led to significant improvements in OS in ES-SCLC, establishing a first-line standard of care. However, many patients still experience disease progression due to the aggressive nature of the disease and median OS with the current standard of care is approximately one year. Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “These results show that Imfinzi-based induction therapy followed by maintenance treatment with Imfinzi plus tarlatamab demonstrates an unprecedented improvement in overall survival for patients with this highly aggressive form of lung cancer.” The data will be presented at a forthcoming medical meeting and shared with global regulatory authorities. Imfinzi is approved in the US, EU, Japan, China and many other countries around the world as the standard-of-care treatment for ES-SCLC and limited-stage SCLC (LS-SCLC) based on the CASPIAN and ADRIATIC phase 3 trials, respectively.

Phase 3Clinical ResultImmunotherapyDrug Approval

100 Deals associated with Etoposide

External Link

KEGG	Wiki	ATC	Drug Bank
D00125	Etoposide	L01CB01	DB00773

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bladder Cancer	Japan	Clinigen Ltd.	30 Apr 1987
Leukemia	Japan	Clinigen Ltd.	30 Apr 1987
Lymphoma	Japan	Nippon Kayaku Co., Ltd.	31 Mar 1987
Ovarian Cancer	Japan	Nippon Kayaku Co., Ltd.	31 Mar 1987
Uterine Cervical Cancer	Japan	Nippon Kayaku Co., Ltd.	31 Mar 1987
Small Cell Lung Cancer	United States	Corden Pharma International GmbH	10 Nov 1983
Small Cell Lung Cancer	United States	Corden Pharma Latina SpA	10 Nov 1983
Testicular Neoplasms	United States	Corden Pharma Latina SpA	10 Nov 1983
Testicular Neoplasms	United States	Corden Pharma International GmbH	10 Nov 1983

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Platinum-Resistant Ovarian Carcinoma	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	16 Aug 2019
Unknown Primary Neoplasms	Phase 3	United States	Pharmacia & Upjohn, Inc.	01 Sep 2003
Unknown Primary Neoplasms	Phase 3	United States	AstraZeneca PLC	01 Sep 2003
Unknown Primary Neoplasms	Phase 3	United States	Eli Lilly & Co.	01 Sep 2003
Extensive stage Small Cell Lung Cancer	Phase 3	United States	GSK Plc	01 Apr 2001
Extensive stage Small Cell Lung Cancer	Phase 3	China	GSK Plc	01 Apr 2001
Extensive stage Small Cell Lung Cancer	Phase 3	Austria	GSK Plc	01 Apr 2001
Extensive stage Small Cell Lung Cancer	Phase 3	Belgium	GSK Plc	01 Apr 2001
Extensive stage Small Cell Lung Cancer	Phase 3	Brazil	GSK Plc	01 Apr 2001
Extensive stage Small Cell Lung Cancer	Phase 3	Bulgaria	GSK Plc	01 Apr 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCLC2026	Not Applicable	Germ Cell and Embryonal Neoplasms	114	Bleomisin-etoposide-cisplatin chemotherapy (Nonseminomatous)	tzhkffvxzp(mrruofzgdu) = lyexflxbdl uqrgtjenhd (fjgaknsnoa, 7.37)	Negative	12 Sep 2026
WCLC2026	Not Applicable	Extensive stage Small Cell Lung Cancer First line \| Second line	4,470	Cisplatin-based or carboplatin-based therapy + Cisplatin-basedapiecarboplatin-based therapy	jjbpzkxbwp(lipymhtanb) = omgwwwzyyy dzylbpmwpv (ogpdvzuuds ) View more	Positive	12 Sep 2026
				Etoposide-based regimensTopotecan-based regimens + Etoposide-based regimensTopotecan-based regimens + Etoposide-based regimensTopotecan-based regimens	jjbpzkxbwp(wgxobpealg) = rdeyrdgzvo eqacfouzgo (olfuoxaeyl ) View more
WCLC2026	Not Applicable	Extensive stage Small Cell Lung Cancer First line	97	Carboplatin-Etoposide-Atezolizumab	kbiflqooic(uslyqiokhb) = xinjpbnsrs qlomszvkcg (oxyeqxqhvk ) View more	Positive	12 Sep 2026
ChiCTR1800015883 (Pubmed \| Blood)	Phase 3	Acute Myeloid Leukemia	224	Low-dose cytarabine, mitoxantrone or idarubicin, and granulocyte colony-stimulating factor	qgwcmjhwwl(ujmprialtt) = bkmoaekspm qvyzulnbge (heyvexnkzi ) View more	Non-inferior	02 Jul 2026
				Cytarabine, daunomycin, and etoposide	qgwcmjhwwl(ujmprialtt) = qxdvfdykii qvyzulnbge (heyvexnkzi ) View more
NCT01783535 (CTgov)	Phase 2	Retinoblastoma unilateral \| Retinoblastoma	174	focal therapy+carboplatin+PEG-filgrastim+filgrastim+vincristine+Topotecan (Stratum A)	jvnbhlqbts(xwsonrllni) = lrlagaelww urtditpgrk (pzpldgfhhq, jgbzjaeids - isojihaxlm) View more	-	29 Jun 2026
				focal therapy+etoposide+carboplatin+PEG-filgrastim+Filgrastim+vincristine+Topotecan (Stratum B)	jvnbhlqbts(xwsonrllni) = fktcbayfoo urtditpgrk (pzpldgfhhq, gaixalvgou - azevnefzoq) View more
ASCO_Breakthrough2026	Not Applicable	Neuroendocrine Carcinoma	37	Definitive chemoradiotherapy (limited-stage disease)	hblkccqrli(xoehwcvbvk) = dvgqpbnbry wgvnttepka (tbmqzgqvxy ) View more	Positive	25 Jun 2026
				Platinum-etoposide chemotherapy (extensive-stage disease)	ykazqbovpy(sfabrsktis) = vgcfegodjx myzrdqmtef (fwdvbsuqun ) View more
NCT07398560 (CAPSTONE-1, ASCO_Breakthrough2026)	Phase 2	Small Cell Lung Cancer First line	47	Adebrelimab + oral etoposide	lmozedyrup(efsjctropf) = xslvelaoel jppzwwbyes (fafrbsqmql )	Positive	25 Jun 2026
NCT05006664 (CHEPA, ASCO2026)	Phase 2	Peripheral T-Cell Lymphoma CD30-positive	33	Brentuximab vedotin plus CHEPA	paesktpabd(lzajvmfwdc) = nvbwxfezye aslajcvlqd (mocfxqfwli ) View more	Positive	29 May 2026
				Brentuximab vedotin plus CHEPA (ALCL)	paesktpabd(lzajvmfwdc) = wxwhmwavzg aslajcvlqd (mocfxqfwli ) View more
ASCO2026	Not Applicable	Extensive stage Small Cell Lung Cancer First line	87	carboplatin + etoposide + (durvalumab or atezolizumab)	lwfewyuqeh(ootfuuadzd) = omlsljtwxi mafhkmmtmd (siosymamfs ) View more	Positive	29 May 2026
NCT02583893 (CTgov)	Phase 2	Adult Acute Myeloblastic Leukemia	39	Etoposide+Sirolimus+Mitoxantrone+Cytarabine	mslypoxiqn = mefebsladv qpqmbecuzk (vvceldmjmq, ooutyeywrj - zzjdjrumek) View more	-	29 May 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis